Business Context and Reporting Period
Company: Wilson Greatbatch Technologies, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Wilson Greatbatch Technologies, Inc.)
Filing Type: Form 10-K Annual Report
Period Ended: December 31, 2004
Business Overview: The Company operates two segments: Implantable Medical Components (IMC), providing batteries, capacitors, and components for implantable medical devices (IMDs); and Electrochem Power Solutions (EPS), providing high-performance batteries for commercial applications (oil & gas, aerospace, oceanographic). The Company serves a concentrated customer base, with three major medical customers (Guidant, St. Jude Medical, Medtronic) accounting for approximately 70% of total sales in 2004.
Key Financial Metrics
| Metric (in thousands) | 2004 | 2003 |
|---|---|---|
| Total Sales | $200,119 | $216,365 |
| Gross Profit | $80,722 | $89,828 |
| Gross Margin | 40.3% | 41.5% |
| Operating Income | $26,940 | $38,200 |
| Net Income | $16,257 | $23,288 |
| Diluted EPS | $0.75 | $1.05 |
| Operating Cash Flow | $45,166 | $54,801 |
| Working Capital | $134,399 | $170,455 |
| Total Assets | $479,938 | $438,243 |
| Long-Term Debt | $170,652 | $170,928 |
| Cash & Equivalents | $89,473 | $119,486 |
Material Changes vs. Prior Period
- Revenue Decline: Total sales decreased 8% to $200.1 million. The IMC segment declined 9% primarily due to lower demand from a major customer for wet tantalum capacitors (sales to this customer dropped $27.0 million) and pricing pressures. The EPS segment grew 5% driven by increased oil and gas demand.
- Profitability Compression: Net income fell 30% to $16.3 million. Operating income dropped 29% to $26.9 million. Gross margin decreased 120 basis points due to lower selling prices and excess capacity costs at the wet tantalum capacitor plant.
- Expense Increases: "Other operating expense" surged 343% to $4.6 million, driven by a $2.0 million charge to acquire patents covering wet tantalum capacitor technology, $0.8 million in severance costs from a 7% workforce reduction, and facility start-up costs.
- Capital Expenditures: Capital spending increased significantly to $38.4 million (from $11.9 million in 2003) to fund new manufacturing facilities in Alden, NY, and Tijuana, Mexico, as well as an Oracle ERP system.
- Acquisition: Acquired NanoGram Devices Corporation in March 2004 for approximately $45.7 million to gain nanotechnology capabilities.
Guidance, Outlook, and Risks
- Strategic Consolidation: Management announced plans to consolidate capacitor and battery manufacturing into a new facility in Alden, NY, and consolidate EMI filtering operations into a new facility in Tijuana, Mexico. These moves are expected to incur one-time costs of approximately $8.0 million to $9.4 million in 2005.
- Product Outlook: The Company expects double-digit growth in the CRM and Neuro markets over the next 3-5 years. New Q-Series medical batteries are expected to drive growth in 2005.
- Customer Concentration Risk: Heavy reliance on three customers (Guidant, St. Jude, Medtronic) for 70% of sales creates significant vulnerability to customer-specific demand shifts or pricing pressure.
- Accounting Changes: Adoption of SFAS 123(R) in 2005 is expected to reduce net income by approximately $1.4 million due to the expensing of stock-based compensation.
- Legal Contingencies: The Company is defending a lawsuit from a former non-medical customer alleging misuse of proprietary information; potential loss is estimated between $0 and $1.7 million.
Investor Verification Checklist
- Customer Concentration: Verify the stability of relationships with Guidant, St. Jude Medical, and Medtronic, which collectively represent 70% of revenue.
- Patent Acquisition Rationale: Assess the strategic value of the $2.0 million patent acquisition charge and its impact on future competitive positioning in wet tantalum capacitors.
- Consolidation Costs: Monitor the execution of the 2005 facility consolidations (Alden, NY and Tijuana, Mexico) and the associated one-time costs ($8M-$9.4M) to ensure they do not materially impact near-term earnings.
- Inventory Levels: Review inventory balances ($34.0 million) relative to the 9% sales decline to assess potential obsolescence or write-down risks.
- Convertible Debt: Review the terms of the $170 million convertible subordinated notes (due 2013) and the potential dilution impact if conversion conditions are met.